72 results about "Basal bolus" patented technology

The invention discloses a hypoglycemic composition containing supramolecular group composite peptide. The hypoglycemic composition comprises collagen peptide, soybean peptide, bitter gourd peptide, bamboo leaf flavone, L-carnitine and the like. The composition prepared by selecting raw material components of specific types and dosages has the effects of remarkably reducing the glucose level and increasing the insulin level, and part of the composition can also cooperate with metformin to achieve the effects of enhancing the effect of reducing blood sugar and improving or preventing type 2 diabetes mellitus. Therefore, the method can be used for developing functional foods and medicines and has a considerable market prospect.

The application discloses a benzothiophenone derivative, a preparation method and application thereof. The benzothiophenone derivative, a tautomer, an optical isomer, a hydrate, a solvate, a pharmaceutically acceptable salt or a prodrug thereof, and the chemical structure of the benzothiophenone derivative is shown as formula (I), wherein R is any one of the following groups: a substituted alkane and N-benzyl-2-chloroformamide. The benzothiophenone derivative can regulate a PPARγ target as an anti-type 2 diabetes drug, can reserve insulin sensitivity, can avoid related side effects caused by a PPARγ full agonist, and has a 'highly efficient and safe' hypoglycemic effect.

The present disclosure relates to poly alpha-1,6-glucan ether compounds comprising poly alpha-1,6-glucan substituted with at least one positively charged organic group and having a degree of substitution of about 0.001 to about 3.0. The poly alpha-1,6-glucan comprises a backbone of glucose monomer units, wherein greater than or equal to 40% of the glucose monomer units are linked via alpha-1,6 glycosidic bonds, and optionally about 3% of the backbone glucose monomer units have branches via alpha-1,2 and / or alpha-1,3 glycosidic bonds. Compositions comprising poly alpha-1,6-glucan ether compounds can be used in various applications.

The invention provides a glucose hydrogel optical fiber sensor and a preparation method thereof. The glucose hydrogel optical fiber sensor comprises an optical fiber and a glucose fluorescence sensing module fixedly carried on the end face of the optical fiber. Wherein the optical fiber comprises a double-layer hydrogel optical fiber which comprises an inner fiber core and an outer cladding. The glucose fluorescence sensing module is formed by fixing a glucose fluorescence probe containing a boric acid group and a terminal amino group through a covalent reaction between the amino group and an epoxy group in the hydrogel network. The glucose hydrogel optical fiber sensor has excellent performance, high sensitivity and good selectivity, and can realize stable and real-time detection of glucose concentration in a complex physiological environment. The sensor is flexible in structure and good in biocompatibility, does not depend on enzyme reaction, and avoids the problem of signal drift caused by enzyme inactivation; meanwhile, the sensor is good in repeatability, can be integrated with other optical sensing modules to realize multi-parameter synchronous monitoring, and is suitable for long-term dynamic monitoring application in vivo.

The invention discloses a sulfonated MXene sensing layer, a preparation method thereof and a biosensor, and belongs to the technical field of electrochemical sensors. The sensing layer contains a sulfonated MXene material, and the sulfonated MXene material is obtained by performing covalent bond modification on a sulfonic acid group on the MXene material. According to the preparation method, sulfonic acid groups are covalently grafted on the surface of MXene through plasma treatment, so that the MXene has high specific surface area, excellent electron conductivity, efficient enzyme immobilization capability and H2O2 catalytic decomposition activity. The biosensor constructed based on the sensing layer comprises a flexible substrate, a three-electrode system and a limited diffusion layer, the response speed, the detection precision, the stability and the anti-interference performance (such as uric acid resistance and ascorbic acid resistance) of the sensor are remarkably improved, and the biosensor is particularly suitable for being applied to an implantable continuous glucose monitoring system.

The invention relates to a lipid molecule, and a composition and application thereof. The core structure of the lipid-like molecule covers a two-dimensional plane structure and a plurality of three-dimensional structures, and endows the LNP with adjustable membrane tissue characteristics and intracellular transport behaviors, so that a new strategy of adjusting delivery performance from the structural level is realized. In addition, part of the ionizable lipid is introduced into a fluorine substituent group, so that the internal hydrophobic interaction and colloidal stability of the LNP are improved, and the in-vivo delivery persistence is prolonged. The invention also provides a component-simplified LNP delivery system based on programmable regulation and control of ionizable lipid chemical bonds, which is different from the traditional strategy of needing to remove hepatic tropism components (such as cholesterol) or additionally introduce targeted regulation and control lipid (a fifth component) to realize organ targeting. Selective delivery of organs such as liver, spleen, lung, pancreas and the like can be realized under the condition of retaining cholesterol only by changing the type of a chemical bond between an aliphatic chain and a core structure in the ionizable lipid.

The disclosure concerns a use of a compound for the preparation of an additive, a premix or a food or fodder, for animal feeding, said compound corresponding to the following formula:in whichR1 is selected from C1-11 alkyl groups;R2 is selected from C1-20 alkyl groups; CmH2m—OR4; CmH2m—NHR4 where R4 is selected from H and C(O)—C1-11 alkyl and m is equal to 0 or represents an integer from 1 to 11;R3 is selected from H and C1-20 alkyl groups;n is 0 or an integer from 1 to 10; andk is an integer from 1 to 10;or a salt of said compound.

The present invention belongs to the technical field of insulin derivatives. Disclosed are a phenylboronic-acid-based insulin derivative, and a preparation method therefor and the use thereof. The provided phenylboronic-acid-based insulin derivative has a good glucose-responsive release function, wherein the phenylboronic acid group binds to a glycosyl protein to generate a phenylboronic acid ester bond, thereby generating an insulin and glycosyl protein complex in situ in blood. When the concentration of glucose in the blood is high, the glucose specifically cleaves the phenylboronic acid ester bond, thereby releasing the insulin. The provided phenylboronic-acid-based insulin derivative achieves stable and rapid glucose-responsive insulin release, which can steadily and persistently maintain the blood glucose of a diabetic subject within the normal range with almost no occurrence of hypoglycemia.

The invention relates to the technical field of food-grade materials, in particular to a food-grade porous material and a preparation method thereof. The preparation method comprises the following steps: gradually carrying out enzymolysis on corn flour by alkaline protease and amylase under the conditions of proper temperature and pH, continuously stirring, adding food-grade vegetable gum, and forming porous glycoprotein under the assistance of ultrasonic waves; the porous glycoprotein is uniform in pore size and is 0.5-3 microns, and the surface of the porous glycoprotein is rich in functional groups, so that the porous glycoprotein has good adsorption performance and has very high adsorbability on hydrophobic compounds such as metal ions, pesticide residues, kitchen oil stains and the like. The preparation process is simple, chemical reagents do not need to be introduced, and safe and non-toxic substances are completely adopted as materials for preparing the porous material, so that the product is food-grade, small in damage to human bodies and the environment and wide in application in the food field.

The invention relates to physically stable compositions in the form of an injectable aqueous solution, having a pH between 6.0 and 8.0, comprising at least: a) a basal insulin having an isoelectric point (pI) between 5.8 and 8.5 and b) a co-polyamino acid bearing carboxylate charges and at least one hydrophobic radical.

The invention discloses a partial acylated non-natural sugar for metabolic labeling and application, the partial acylated non-natural sugar is a mannose type of a pyranose structure, and 1-hydroxyl and 6-hydroxyl are protected by hydrophobic groups. According to the method, the advantages of existing non-natural sugar are taken into consideration, it is guaranteed that the non-natural sugar can be efficiently utilized by cells, S side reaction of the non-natural sugar and cysteine in protein in the metabolism process is effectively avoided, and meanwhile efficient metabolism marking is achieved. In a cell test, the use concentration of the 1, 6-diacylated non-natural sugar is one order of magnitude lower than that of the non-natural sugar without the protecting group.

The invention belongs to the technical field of protein beverages, and particularly relates to a composite peptide beverage and a preparation process thereof. The active ingredients of the drink comprise calf thymosin, cattle spleen protein peptide, hemoglobin peptide, bone collagen peptide and collagen peptide in a weight ratio of (2-3): 1: 1: 1: 1. The pH value of the system is adjusted to 3.5-4.5, so that each peptide molecule is positively charged under the acidic condition, the electrostatic repulsion and hydration among molecules are enhanced, and bitter groups are effectively masked. The flavoring agent is compounded by DL-malic acid, crystalline fructose, xylitol and sucralose according to the weight ratio of (0.6-1): 1: 0.4: (0.03-0.04), and the sour and sweet taste and flavor coordination are synergistically improved. The preparation method comprises the following steps: dissolving the DL-malic acid in purified water, dissolving the uniformly mixed active components in purified water at 40-60 DEG C, respectively adding other flavoring agents, stabilizing agents and essence, and finally filtering to obtain the product. The problem of bad flavor of the peptide is solved, so that the beverage is appropriate in taste, harmonious in flavor and easy to accept.

The invention discloses a pyrrole biphenyl derivative compound as well as a preparation method and application thereof in pharmacy, and belongs to the technical field of chemical medicine raw material medicine and preparation manufacturing. The compound has a structure as shown in # imgabs0 #. The compound is specifically combined with SGLT-2 protein through a pyrrole-benzene conjugated system, the glucose transport function of the SGLT-2 protein is inhibited, and the IC50 value of the SGLT-2 protein reaches 15-105 nM. The traditional Chinese medicine composition is suitable for preparing medicines for treating non-alcoholic liver diseases, solid tumors, hematological malignant tumors and autoimmune diseases, and especially has a remarkable effect on abnormal glycolipid metabolism of liver cells and energy deprivation of tumor cells. The compound has deuterated group enhanced metabolic stability, and can be prepared into dosage forms such as tablets, capsules, injection and the like.

The present disclosure provides a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein: X1 is CH or N; p is 0, 1 or 2; wherein: each R1 is a substituent on any C atom and is independently selected from the group consisting of F, Cl, C1-3 alkyl and C1-3 alkoxy wherein the C1-3 alkyl and C1-3 alkoxy may be independently optionally substituted by one or more F; rN is selected from H and Me; n is 0, 1 or 2; m is 0 or 1; q1 is CH or N; q2 is CH or N when neither n nor m is 0; when both n and m are 0, Q2 is CH; when n is 0 or 1, Q3 is CH; when n is 2 and Q2 is N, Q3 is CH; when n is 2 and Q2 is CH, Q3 is CH or O; r2a and R2b are substituents on the same or different C atoms other than at Q1 or Q2, each independently selected from H, F and C1-3 alkyl, or R2a and R2b together form a-(CH2) r-group wherein r is 1, 2 or 3; q4 is a single bond or-NR4C (= O); r4 is H or Me; 0, 1, or 2 of Y1, Y2, Y3, Y4, and Y5 is N, otherwise C; each R3 is a substituent on any C atom at Y1, Y2, Y3, Y4 and Y5 and is independently selected from the group consisting of F, Cl, CN, C1-3 alkyl and C1-3 alkoxy wherein the C1-3 alkyl and C1-3 alkoxy may be independently optionally substituted by one or more F; q is 0, 1 or 2; wherein the linker is attached to any available C atom at Y4 and Y5; the linker is a saturated or partially or fully unsaturated framework comprising a C atom and an H atom and at least one heteroatom, wherein the framework has a length of 5 to 26 atoms connecting the endpoints'a 'and'b' and between'a 'and'b'; wherein the framework may comprise one or more linear and / or branched chains and / or rings and are optionally substituted by one or more F on any available C atom; and W is an E3 ubiquitin ligase cerebron binding agent unit.

[Problem] The purpose of the present invention is to provide a polymerizable boronic acid compound that has a structure different from both an azobenzene moiety and an acrylamide phenylboronic acid structure and makes it possible to detect a change in glucose concentration by forming glucose and a cyclic boronic acid ester. [Solution] The problem is solved by a polymerizable boronic acid compound or the like represented by general formula (1) (in the formula, at least one of R1 to R7 denotes a substituent having a polymerizable group, and the remaining moieties independently denote a substituent selected from the group consisting of a hydrogen atom, a hydroxy group, a carboxyl group, an amino group, and an alkyl group).

A compound comprising a peptide chain which is an analogue of amylin, a terminal —NH2 group bound to the C terminal of the peptide chain, and an alkylene or alkenylene chain attached at the other end of the peptide chain or a derivative of the compound; or a salt or solvate of the compound or of the derivative. Compounds, derivates and salts, and related compositions are suitable for the prevention or treatment of diabetes, obesity, heart disease, stroke and non-alcoholic fatty liver disease, improving insulin release in a subject, improving carbohydrate metabolism in a subject, improving the lipid profile of a subject, improving carbohydrate tolerance in a subject, reducing appetite, reducing food intake, and / or reducing calorie intake, and related purposes.

A compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X 1 is CH or N, p is 0, 1, or 2, where each R 1 is a substituent on any C atom and is independently selected from F, Cl, C 1~3 alkyl, and C 1~3 alkoxy, and the C 1~3 alkyl and C 1~3 alkoxy may each be optionally substituted by one or more Fs, R N is selected from H and Me, n is 0, 1, or 2, m is 0 or 1, Q 1 is CH or N, and when both n and m are other than 0, Q 2 is CH or N, and when both n and m are 0, Q 2 is CH, and when n is 0 or 1, Q 3 is CH, and when n is 2 and Q 2 is N, Q 3 is CH, and when n is 2 and Q 2 is CH, Q 3 is CH or O, and R 2a and R 2b are substituents on the same or different C atoms other than Q 1 or Q 2 and are each independently selected from H, F, and C 1~3 alkyl, or R 2a and R 2b together form a -(CH2) r - group, where r is 1, 2, or 3, Q 4 is a single bond or -NR 4 C(=O), R 4 is H or Me, Y 1 , Y 2 , Y 3 , Y 4 , and Y 5 of which 0, 1, or 2 are N and otherwise C, and each R 3 is Y1, Y 2 , Y 3 , Y 4 , and Y 5A substituent on any C atom, independently of F, Cl, CN, C 1~3 Alkyl and C 1~3 Selected from alkoxy, the C 1~3 Alkyl and C 1~3 The alkoxy can be independently and optionally substituted by one or more Fs, where q is 0, 1, or 2, and the linker is Y. 4 and Y 5 A compound of formula (I) or a pharmaceutically acceptable salt thereof, bonded at any available C atom, the linker being a saturated, partially or fully unsaturated skeleton comprising C and H atoms and at least one heteroatom, the skeleton having bond endpoints "a" and "b" and having a length of 5 to 26 atoms between "a" and "b", the skeleton may contain one or more linear and / or branched and / or ring chains, optionally substituted on any available C atom with one or more F, and W being an E3 ubiquitin ligase cereblon binding unit. [Formula 1] JPEG2026510359000635.jpg38128

[Problem] To provide a dental caries suppression composition that is, in comparison with conventional anti-dental caries agents, capable of providing an even higher level of suppression of caries. [Solution] This composition contains: (A) an oligosaccharide that has a cyclic structure comprising glucose and / or a glucose derivative as a structural unit; and (B) a sugar other than the component (A). The component (A) is a cyclodextran and / or a cyclodextran derivative. The cyclodextran derivative has at least one of the alcoholic hydroxyl groups of cyclodextran substituted with another polar group. According to the present invention, the composition contains: (A) an oligosaccharide that has a prescribed cyclic structure comprising glucose and / or a glucose derivative as a structural unit; and (B) a sugar other than the component (A). The components (A) and (B) interact with one another in such a manner as to suppress dental caries. Consequently, suppression of dental caries at a higher level than that achieved by conventional anti-dental caries agents is realized.

A compound comprising a peptide chain which is an analogue of amylin, a terminal - NH2 group bound to the C terminal of the peptide chain, and an alkylene or alkenylene chain attached at the other end of the peptide chain or a derivative of the compound; or a salt or solvate of the compound or of the derivative. Compounds, derivates and salts, and related compositions are suitable for the prevention or treatment of diabetes, obesity, heart disease, stroke and non-alcoholic fatty liver disease, improving insulin release in a subject, improving carbohydrate metabolism in a subject, improving the lipid profile of a subject, improving carbohydrate tolerance in a subject, reducing appetite, reducing food intake, and / or reducing calorie intake, and related purposes.

The invention discloses a linalool glycosylation derivative as well as preparation and application thereof. The structure of the linalool glycosylation derivative is shown as a formula (I), R1, R2, R3, R4 and R5 groups are independently selected from H or a linalool group, and the preparation method comprises the following steps: taking linalool and glucose as raw materials, and catalytically synthesizing the linalool glycosylation derivative by using beta-glucosidase under an acidic heating condition. According to the linalool glycosylation derivative, the water solubility, the antibacterial property, the stability and the fragrance durability of the linalool glycosylation derivative are greatly improved by introducing the glucosyl group into the linalool. The derivative is suitable for various daily chemical products with antibacterial properties, and has a better industrial application prospect.

This invention discloses a pyrrolobenzene derivative compound, its preparation method, and its pharmaceutical application, belonging to the field of chemical pharmaceutical raw materials and formulation manufacturing technology. The compound has the structure shown. This compound specifically binds to the SGLT-2 protein through a pyrrolobenzene conjugated system, inhibiting its glucose transport function and affecting the IC50 of SGLT-2. 50 Values ​​range from 15 to 105 nM. Suitable for preparing drugs to treat non-alcoholic liver disease, solid tumors, hematological malignancies, and autoimmune diseases, especially effective against abnormal glucose and lipid metabolism in hepatocytes and energy deprivation in tumor cells. The compound possesses enhanced metabolic stability due to its deuterated group and can be formulated into tablets, capsules, injections, and other dosage forms.

A drug delivery system for administering a GLP-1 agonist therapy includes a reservoir configured to contain a GLP-1 agonist, a pump in fluid communication with the reservoir and configured to deliver the GLP-1 agonist, a controller operatively coupled to the pump, and a user interface operatively coupled to the controller. The controller is programmed to deliver a basal dose of the GLP-1 agonist continuously over a 24-hour period and deliver at least one bolus dose of the GLP-1 agonist in addition to the basal dose. The system allows for independent adjustment of basal and bolus doses based on patient-specific parameters, enabling personalized GLP-1 agonist therapy administration.

The present application discloses a phenyl boronic acid compound, which contains a phenyl boronic acid group and a carbon-carbon double bond group, and the phenyl boronic acid group can be combined with glucose. The present application also discloses a polymer, which is obtained by free radical copolymerization of the above-mentioned phenyl boronic acid compound, a monomer containing A and an initiator in a solvent. The present application further discloses an insulin sustained-release preparation containing the above-mentioned polymer, which has different insulin release rates under different glucose concentrations, and can accelerate the release of insulin under a hyperglycemic environment to reduce blood glucose. The present application further discloses a preparation method of the above-mentioned insulin sustained-release preparation, which self-assembles the negatively charged insulin and the positively charged double-phenyl boronic acid modified polymer into the insulin sustained-release preparation through electrostatic interaction, and has the characteristics of high loading rate. The prepared insulin sustained-release preparation can release insulin, and the released insulin can bind to insulin receptors in the body to reduce blood glucose level.

The invention relates to the technical field of biological medicine, in particular to a compound and a preparation method thereof, a photo-thermal agent and application of the photo-thermal agent in obesity treatment. The compound has a structure as shown in a formula I in the specification, wherein R is selected from at least one of anthracene-containing groups, dibenzothiophene-containing groups or carbazole-containing groups, and X is selected from at least one of halogen atoms, PF6 <-> and BF4 <->. The compound provided by the invention has mitochondrial targeting property and good photothermal conversion capability, and can realize obesity treatment by promoting the browning process of white adipose tissues.

The invention discloses a glucose responsive microneedle, a microneedle patch and a preparation method and application thereof. The glucose responsive microneedle comprises a polymer shell layer with glucose responsiveness and a solid insulin solid core, wherein the thickness of the polymer shell layer is 50 to 150 [mu] m; polymer monomers in the polymer shell layer comprise phenylboronic acid monomers with glucose response groups and positively charged liquid monomers; the positively charged liquid monomer is an acrylic ester compound containing a substituted amino group; the raw materials of the polymer shell layer do not contain a cross-linking agent. The glucose responsive microneedle provided by the invention has high drug loading capacity, can realize accurate and long-time drug delivery when being used for delivering blood glucose regulating hormone insulin, has high stability and basically no toxicity, and has relatively good regulation and control capability on blood glucose.

The invention belongs to the technical field of medicines, and discloses synthesis and application of polycholic acid-short chain fatty acid with a novel structure. The polymer is formed by connecting polycholic acid (as a main chain) with one or more short-chain fatty acids through covalent bonds. The polycholic acid is introduced as a skeleton structure of the polymer and the short-chain fatty acid is introduced as a side chain group, so that the functional polymer with biological activity is constructed. The invention also provides a nano-drug prepared by taking the polymer as a carrier. The nano-drug has good biocompatibility and drug loading capacity, effectively improves the effects of losing weight, reducing fat and relieving liver inflammation, effectively relieves liver fibrosis and aging, can enhance the fatty liver treatment effect and further reduce insulin resistance, and has wide clinical application prospects.

The application discloses a sulfonated MXene sensing layer, a preparation method thereof and a biosensor, and belongs to the technical field of electrochemical sensors. The sensing layer contains a sulfonated MXene material, and the sulfonated MXene material is obtained by covalently grafting sulfonic acid groups on the MXene material. The sulfonic acid groups are covalently grafted on the surface of the MXene through plasma treatment, so that the sulfonic acid groups have high specific surface area, excellent electron conductivity, high enzyme immobilization capacity and H2O2 catalytic decomposition activity. The biosensor based on the sensing layer comprises a flexible substrate, a three-electrode system and a diffusion-limiting layer, and the response speed, detection accuracy, stability and anti-interference performance (such as anti-uric acid and anti-ascorbic acid) of the biosensor are significantly improved, and the biosensor is particularly suitable for applications in an implantable continuous glucose monitoring system.

The invention relates to a fat composition and a nutritional composition comprising such fat composition. The nutritional composition is particularly suitable for therapeutic applications in treating gut discomfort and / or constipation as well as in non-therapeutic applications for reducing the intestinal formation of calcium and magnesium fatty acid soaps. The fat composition comprises a mixture of triacylglycerols (TAG) originating from a bovine milk fat source and a vegetable lipid source, said mixture being characterized by: (a) a content of butanoate groups (C4:0) of 0.5-2.8% by weight based on total weight of fatty acid acyl groups in TAG; (b) a wLCSFA(sn-1,3) of 18.0-35.0% by weight; (c) a mLCFA (sn-1,3) of 48.0-61.0 mol %; and (d) a ratio mLCFA (sn-1,3) / SFA of 0.70-1.25, wherein: —LCFA(sn-1,3) are the long chain fatty acid acyl groups having a chain length of 12 or more carbon atoms at the sn-1 and sn-3 position in TAG; —LCSFA(sn-1,3) are the long chain saturated fatty acid acyl groups having a chain length of 12 or more carbon atoms at the sn-1 and sn-3 position in TAG; —wLCSFA(sn-1,3) is the amount of LCFA(sn-1,3) in % by weight based on total weight of fatty acid acyl groups in TAG; —mLCFA(sn-1,3) is the mole fraction of LCFA(sn-1,3) based on total moles of fatty acid acyl groups in the TAG as expressed in mol %; and—SFA is the mole fraction of saturated fatty acid acyl groups in the TAG as expressed in mol %.

This invention discloses a method for determining glucose content in embryo culture medium. In this invention, proteins and amino acids are filtered from the sample using ultrafiltration centrifuge tubes. High-performance liquid chromatography (HPLC) is used as the detector, and an external standard curve method is employed to detect the glucose content in the embryo culture medium. The pretreatment step of ultrafiltration centrifuge tube filtration eliminates interference from human serum albumin and some amino acids in the embryo culture medium on the determination of the target component, glucose. An amino-based column is specifically selected; the hydroxyl groups in glucose form hydrogen bonds with the amino groups on the stationary phase of the amino-based column, separating them from other components in the culture medium under the action of the mobile phase, thus achieving separation. The method uses a differential detector to establish an external standard curve for quantitative determination, which is characterized by rapid and simple operation, good repeatability, and accurate results, making it suitable for determining glucose content in embryo culture medium.

The invention discloses a dextran internal gluconic acid imidazoline nano-particle supercritical CO2 corrosion inhibitor and a preparation method and application thereof, and the dextran internal gluconic acid imidazoline nano-particle supercritical CO2 corrosion inhibitor comprises a dextran internal gluconic acid imidazoline nano-particle mixed solution, a dextran internal gluconic acid imidazoline nano-particle mixed solution, a dextran internal gluconic acid imidazoline nano-particle mixed solution and a dextran internal gluconic acid imidazoline nano-particle mixed solution, the structural formula of the components in the glucan gluconic acid imidazoline nano-particle mixed solution is shown in the specification, wherein n is equal to 60-80. The glucan inner gluconic acid imidazoline nano-particle supercritical CO2 corrosion inhibitor provided by the invention has an amide group and a large number of N and O groups with relatively strong polarity, and the groups can obviously improve the adsorption capacity of the corrosion inhibitor and enhance the film-forming capacity; the corrosion inhibitor is adsorbed on the surface of steel to form an aggregation type nano corrosion inhibitor film, so that the structure that a common corrosion inhibitor is adsorbed into a molecular film is changed, and the corrosion problem of supercritical CO2-water mixed-phase system steel is effectively solved.